The TearLab Osmolarity System and Osmolarity Test Card have been submitted to the FDA for premarket authorization in the US, according to an announcement from the manufacturer of TearLab, Occulogix.
The TearLab Osmolarity System and Osmolarity Test Card have been submitted to the FDA for premarket authorization in the US, according to an announcement made by TearLab's manufacturer, Occulogix.
To support the application, OcuSense, a subsidiary of Occulogix, has conducted a multicentre safety and efficacy study of the System, which requires <50 nanolitres of tears to measure osmolarity. OcuSense will announce its results at this year's meeting of the American Academy of Ophthalmology.
The TearLab System, which is CE marked, is currently available in selected European countries.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.